Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
DURHAM, N.C., March 09, 2017 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced that Jeff Wolf, Heat’s Founder and Chief Executive Officer, will present at the 29th Annual ROTH Conference in Newport Beach, CA on Monday, March 13, 2017, at 5:30 p.m. Pacific Time.
The link to the live audio webcast and replay of the presentation may be accessed on Heat’s corporate website at http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that are designed to activate a patient’s immune system against cancer utilizing an engineered form of gp96, a protein that activates the immune system when cells die. Heat’s highly specific T cell-stimulating therapeutic vaccine platform technologies, ImPACT and ComPACT, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 1b trial with HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC) and a Phase 2 trial with HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC).
Heat’s wholly-owned subsidiary, Zolovax, Inc., is developing therapeutic and preventative vaccines to treat infectious diseases based on Heat’s gp96 vaccine technology, with a current focus on the development of a Zika vaccine in conjunction with the University of Miami.
For more information, please visit www.heatbio.com.
Contact: Jennifer Almond Investor and Media Relations 919-240-7133 [email protected]
